A brain-computer interface (BCI) is a system that reads electrical signals from your brain and translates them into commands that control an external device, like a computer cursor, a robotic arm, or a speech synthesizer. It bypasses the normal pathway of brain-to-nerve-to-muscle entirely, creating a direct link between thought and action. The technology is already helping people with paralysis type, speak, and interact with the world, and the global BCI market is projected to grow from $1.74 billion in 2022 to $6.2 billion by 2030.
How a BCI Reads Your Thoughts
Every thought, movement, and intention you have produces tiny electrical signals in your brain. A BCI captures those signals through electrodes, then runs them through a processing pipeline that cleans up the data, identifies meaningful patterns, and converts those patterns into specific commands. The raw brain signal is noisy, so the system first filters out interference and isolates the frequency bands that correspond to the mental task at hand. If you imagine moving your left hand, for instance, the pattern of electrical activity differs from imagining your right hand or your feet. The BCI learns to tell these apart.
Artificial intelligence plays a central role in that decoding step. Modern systems use deep learning models, including convolutional networks, recurrent networks, and transformer architectures (the same family of AI behind large language models), to map brain activity onto intended outputs. A neural speech decoding framework tested across 48 neurosurgical patients achieved strong accuracy in reconstructing speech spectrograms from brain signals, with the best-performing model reaching a correlation of 0.806 between original and decoded speech. These AI models are what make it possible to go from messy biological signals to fluid, real-time control.
Invasive vs. Non-Invasive Devices
BCIs fall into two broad categories based on how they access brain signals: non-invasive systems that sit outside your skull, and invasive systems that require surgery to place electrodes closer to the neurons themselves.
The most common non-invasive approach is EEG, which uses electrodes placed on the scalp to record electrical activity. It’s safe, portable, and relatively cheap, but the skull and tissue between the electrodes and the brain blur the signal considerably. Other non-invasive methods include functional near-infrared spectroscopy and magnetoencephalography, though these are less practical for everyday BCI use.
Invasive BCIs offer dramatically better signal quality. Microelectrode arrays implanted directly in the brain’s gray matter can detect the firing of individual neurons. Electrodes placed on the brain’s surface (beneath the skull but not penetrating tissue) record local electrical fields with far less noise than scalp-based systems. The tradeoffs are real: higher spatial and temporal resolution, a stronger signal-to-noise ratio, and the ability to target specific brain regions, but at the cost of surgical risk, potential complications, and long-term durability challenges.
What Patients Can Do With BCIs Today
The most striking applications are in restoring communication and movement for people with severe paralysis. Researchers at UC Davis developed a BCI that decodes speech directly from neural signals in a 45-year-old man with ALS, allowing him to communicate by translating his brain’s speech-planning activity into words. A separate system tested finger-movement decoding for typing achieved 90 characters per minute with over 90% accuracy after error correction, matching the speed of handwriting-based brain decoding. For context, that approaches the speed of someone casually typing on a smartphone.
Beyond communication, BCIs are being used to control robotic prosthetic limbs, operate computer cursors, and interact with smart home devices. The common thread is that the person’s intended action, whether speaking a word, moving a finger, or clicking a mouse, gets decoded from brain activity and executed by an external system in real time.
Three Companies Leading Development
Neuralink, founded by Elon Musk, received FDA approval to begin human clinical trials in May 2023. Its device uses 64 ultrathin flexible threads containing 1,024 electrodes that are implanted into the brain, with signals transmitted wirelessly via Bluetooth to a computer for decoding. The system is designed to let people control cursors and robotic arms through thought alone.
Synchron has moved further along in clinical testing and takes a fundamentally different approach. Rather than opening the skull, its Stentrode device is delivered through a catheter inserted into the jugular vein and guided to a blood vessel near the brain’s motor cortex. A study of four patients with severe paralysis found this endovascular approach to be safe and feasible, offering a path to BCI implantation without craniotomy. The recording device connects to a small electronic unit implanted under the skin, which then communicates wirelessly to an external computer.
Precision Neuroscience, founded by a Neuralink co-founder, has developed what it calls a Layer 7 cortical interface: a thin, flexible electrode array that sits on the brain’s surface like a piece of tape, without penetrating tissue. It has been tested in three patients undergoing brain tumor surgery, though it hasn’t yet entered formal FDA trials.
Why Implants Degrade Over Time
One of the biggest unsolved problems with invasive BCIs is that the body treats implanted electrodes as foreign objects. Within weeks to months, the brain’s immune cells surround the electrodes with scar tissue, a process called gliosis. This inflammatory response increases the electrical impedance between the electrode and nearby neurons, weakening the signal over time. In some cases, the chronic inflammation also causes nearby neurons to die, further degrading performance.
The root cause is a mechanical mismatch: brain tissue is extremely soft, while most electrode materials are rigid. That difference creates ongoing micro-damage at the interface, perpetuating the immune response. Researchers are working on softer, more biocompatible electrode materials to reduce this reaction, but high failure rates remain a significant barrier to making implanted BCIs last for years or decades.
Privacy and the Question of “Neurorights”
As BCIs move from research labs into commercial products, a new category of privacy concern has emerged: who owns and controls your neural data? Consumer-grade neurotechnology products often collect brain activity data that isn’t classified as sensitive health information, meaning companies can retain broad rights to access and share it with third parties.
Legal protections are starting to catch up, but unevenly. Chile became the first country to act, passing a 2021 constitutional amendment that explicitly protects “cerebral activity and the information drawn from it” as a constitutional right. In the United States, Colorado, California, and Montana have updated their consumer data privacy laws to include neural data in their definitions of sensitive personal information. The EU’s AI Act takes a different angle, classifying AI-based neurotechnology that uses “significantly harmful subliminal manipulation” as prohibited. These early laws represent a patchwork rather than a comprehensive framework, and the legal landscape will likely shift significantly as the technology becomes more capable and widespread.